REDWOOD SHORES, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. today announced that the FDA has expanded the Indications for Use statement for the latest generation of its Ingestible Sensor technology, enabling the device to be used as an aid in the measurement of medication adherence. To the Company’s knowledge, this is the only device with an FDA-sanctioned claim for measuring medication adherence. An estimated 50% of us do not take our medicines as prescribed, potentially limiting the